Investor Presentaiton
Investor presentation
ADA 2019
Slide 13
An overview of the PIONEER programme
Diet and
exercise
k
OAD
PIONEER 1
Insulin users
PIONEER 2
vs SGLT-2
(Met)
PIONEER 8
vs placebo
(Diet and exercise)
PIONEER 3
vs DPP-4
(1-2 OADs: Met + SU)
PIONEER 4
vs GLP-1/placebo
(1-2 OADs: Met ± SGLT-2)
PIONEER 7
Flexible dose adjustment
vs DPP-4 with extension
(1-2 OADs: Met, SU,
TZD, SGLT-2)
Add-on to insulin
(Insulin + Met)
Special
populations
PIONEER 5
Renal impairment
(± Met, ± SU, or ± insulin)
PIONEER 6
CVOT
(Standard of care)
PIONEER 9
vs GLP-1/placebo, Japan
(Monotherapy)
PIONEER 10
vs GLP-1/placebo, Japan
(1 OAD: SU, TZD,
a-GI, glinide or SGLT-2)
Note: Text in parentheses represents allowed background medications.
CVOT: cardiovascular outcomes trial; DPP-4: dipeptidyl peptidase-4 inhibitor; GLP-1: glucagon-like peptide-1 receptor agonist; Met: metformin; OAD: oral anti-diabetes drug;
PIONEER: peptide innovation for early diabetes treatment; SGLT-2: sodium glucose co-transporter-2 inhibitor; SU: sulphonylurea; TZD: thiazolidinedione; a-GI: alpha-glucosidase inhibitors;
glinide: prandial glucose regulators.
novo nordiskView entire presentation